Figure 4

Body weight and clinical score.

Mice were immunized with MOG _35–55 and monitored 28 days for body weight gain/loss and clinical disease score. (A and B) The variation of body weight has been expressed compared to day of EAE induction (day 0) for each experimental group. Naive mice showed a normal increase in body weight. On the contrary, a significant body weight loss was observed in EAE mice, whereas a relevant body weight gain was found in EAE mice treated with RR-MS patients human periodontal ligament stem cells (hPDLSCs)-derived conditioned medium (hPDLSCs-CM) or purified exosomes/microvesicles (hPDLSCs-EMVs) [A; ****p < 0.0001 vs EAE; **p = 0.0029 vs EAE + hPDLSCs-CM; **p = 0.0030 vs EAE + hPDLSCs-EMVs] and in EAE mice treated with donors hPDLSCs-CM or hPDLSCs-EMVs [B; ****p < 0.0001 vs EAE; **p = 0.0025 vs EAE + hPDLSCs-CM; **p = 0.0026 vs EAE + hPDLSCs-EMVs]. (C and D) Naive mice did not display motor deficit. EAE mice displayed a grading of disease, while significant reduction in the clinical scores was observed in EAE mice treated with RR-MS patients hPDLSCs-CM or hPDLSCs-EMVs [C; ****p < 0.0001 vs EAE; ***p < 0.0009 vs EAE; ****p < 0.0001 vs naive] and in EAE mice treated with donors hPDLSCs-CM or hPDLSCs-EMVs [D; ***p < 0.0008 vs EAE; ***p < 0.0002 vs EAE; ****p < 0.0001 vs naive].